Abstract A consecutive series of 14 patients with hepatic malignant disease treated by palliative hepatic arterial embolisation was reviewed. Twelve patients had hepatic pain from their tumour and two were suffering from the carcinoid syndrome. Six patients died within four weeks of the procedure (group 1) and eight survived for at least 10 weeks (group 2). Factors were sought that might permit prediction of a high risk of early death (group 1). The pre-embolisation angiograms reviewed by a "blind" observer showed no differences in vascularity or tumour size between the groups and no difference in the extent of arterial occlusion after embolisation. The portal vein was patent in all patients. No significant difference was seen between the groups in the pre-embolisation biochemical values, with the exception of lower serum albumin concentrations and higher alkaline phosphatase activities in group 1. All those who died early had serum alkaline phosphatase activities of 45 KAU or above, while six of the eight who survived longer had activities below this value (p <0 02).
I M MURRAY-LYON Introduction
Hepatic arterial embolisation was used as palliative treatment in 14 patients with primary or secondary tumours of the liver; 12 had severe pain and two the carcinoid syndrome. Six patients died within 28 days after embolisation, and at least four of these deaths were attributed to the procedure. Because of this high mortality we abandoned the procedure, but follow up showed that the other eight patients obtained useful palliation and survived for up to 14 months. Radiological and laboratory data obtained before embolisation were therefore analysed in order to see if they might be used to predict a high risk of early death and to permit future use of the treatment in selected patients likely to benefit.
Methods
The case notes and angiograms of 14 consecutive patients with extensive hepatic tumours treated between January 1978 and May 1981 were examined and data obtained just before embolisation extracted (see table II ). The extent of malignant disease within the liver was estimated from the pre-embolisation arteriograms by tracing the outlines of the areas of pathological circulation and expressing them as a percentage of the total area of the liver. Each patient underwent a single hepatic arterial embolisation with combinations of absorbable gelatin sponge (Sterispon), homologous lyophilised dura mater (Lyodura), and human thrombin under antibiotic cover. The aim was completely to occlude the arterial supply to the tumour, and Figure 1 (graded 1 or 2 on a 0-3 scale).1 In group 1 there were five men and one woman with a mean age of 64 years (range 52-77). Group 2 comprised five men and three women with a mean age of 61 (28-77). Table I shows the causes of death of the six who died within 28 days of embolisation. This table also gives the timing of these early deaths together with age and sex and whether or not adjunctive chemotherapy was used. 
Discussion
The death rate in our series, which comprised patients with extensive tumours treated principally for palliation of pain, contrasts with the low or absent mortality in larger series,2 3 where limited embolisation was usually used on several occasions to achieve piecemeal arterial occlusion and total embolisation of the hepatic artery was reserved for patients with limited liver metastases and well preserved liver parenchyma. For palliation we chose to carry out a single embolisation procedure rather than expose the patient to repeated hospital admissions, angiography, and postembolisation pain and fever.
Our study suggests that the serum alkaline phosphatase activity and albumin concentration may be used to select those patients with symptoms who might benefit from our approach. The difference in albumin concentration still remained significant when the three patients with cirrhosis were excluded.
Other studies have suggested several adverse prognostic factors. It is generally agreed that those with the largest tumours are most at risk; however, if the technique is to be used for palliation of pain then large tumours will need to be treated. We found no significant difference in tumour load as assessed angiographically between those who died early and those surviving longer, and a very much larger series would be needed to see if the trend for larger tumours to fall into group 1 proved real. The technique used to assess tumour size probably overestimated the extent of disease, as it ignored the anteroposterior dimensions of the tumour masses. It did, however, provide a rough estimate of the extent of malignant disease. Neither alkaline phosphatase activity nor serum albumin concentration showed any tendency at all to correlate with tumour size.
Kim and colleagues suggested that the tumours that look most vascular after hepatic arterial angiography respond best to arterial embolisation.1 This presumably indicates a greater dependence of these tumours on the arterial rather than portal blood supply. We found a similar though statistically nonsignificant trend.
Experiments in animals show that embolisation of the hepatic artery with relatively large particles of absorbable gelatin sponge results in less derangement of liver function and less risk of hepatic failure or abscess than embolisation of the more peripheral hepatic tree with silicone cement.4 Embolisation of small vessels, however, is more effective in delaying the formation of a collateral circulation. Our technique used combinations of absorbable gelatin sponge, human thrombin, and Lyodura. Absorbable gelatin sponge and strips of Lyodura approximately 1 x 10 mm were used as the initial embolising materials, and human thrombin was added when satisfactory occlusion had not been achieved. Thus our technique may have resulted in relatively proximal arterial occlusion and spared the terminal arteries and arterioles.
Portal venous obstruction is an absolute contraindication to hepatic arterial embolisation and hepatic cirrhosis a relative contraindication; in cirrhosis the liver parenchyma is more dependent on the hepatic arterial supply than normal. Nevertheless, two of the three patients we treated who had cirrhosis survived longer than 28 days; one woman aged 47 died at 11 months, and another woman aged 28 was still alive at three months when she returned to her own country and was lost to follow up.
Jaundice has also been suggested as a relative contraindication to hepatic dearterialisation,5 though this has been disputed.6 Only five of our patients had serum bilirubin concentrations within the normal range (two in group 1, three in group 2), and we did not find the serum bilirubin concentration useful in predicting outcome in this high risk group of patients. Tumours may produce localised intrahepatic biliary obstruction,7 and embolisation experiments in monkeys8 show an increased risk of abscess formation in areas of liver whose biliary outflow is obstructed. Local biliary obstruction may explain the predictive value of the raised serum alkaline phosphatase activity. The preponderance of pancreatic tumours in group 1 is notew;orthy.
Our findings suggest that a weighted combination of serum alkaline phosphatase activity and serum albumin concentration may be used to predict a subgroup of patients with extensive hepatic tumours who can be treated with hepatic arterial embolisation. Our findings could be readily tested in other series retrospectively before clinical application and, if confirmed, would permit safe single palliative embolisation of large painful tumours.
Introduction
Pulmonary disease induced by paraquat has an almost uniformly fatal outcome. We describe a patient in whom the pressure of arterial oxygen fell to 4-6 kPa (34 mm Hg) despite treatment with a combination of cyclophosphamide and prednisolone but whose condition improved after radiotherapy to the lungs. 
